Cited by 257Gut microbiota and healthHistone Deacetylase Inhibitors ResearchProbiotics and Fermented Foods

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.

Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid

Open access

Abstract

Overexpression of histone deacetylase (HDAC) isoforms has been implicated in a variety of disease pathologies, from cancer and colitis to cardiovascular disease and neurodegeneration, thus HDAC inhibitors have a long history as therapeutic targets. The gut microbiota can influence HDAC activity via microbial-derived metabolites. While HDAC inhibition (HDI) by gut commensals has long been attributed to the short chain fatty acid (SCFA) butyrate, the potent metabolic reservoir provided by the gut microbiota and its role in host physiology warrants further investigation in a variety of diseases. Cell-free supernatants (CFS) of 79 phylogenetically diverse gut commensals isolated from healthy human donors were screened for their SCFA profile and their total HDAC inhibitory properties. The three most potent HDAC inhibiting strains were further evaluated and subjected to additional analysis of specific class I and class II HDAC inhibition. All three HDAC inhibitors are butyrate producing strains, and one of these also produced substantial levels of valeric acid and hexanoic acid. Valeric acid was identified as a potential contributor to the HDAC inhibitory effects. This bacterial strain, Megasphaera massiliensis MRx0029, was added to a model microbial consortium to assess its metabolic activity in interaction with a complex community. M. massiliensis MRx0029 successfully established in the consortium and enhanced the total and specific HDAC inhibitory function by increasing the capacity of the community to produce butyrate and valeric acid. We here show that single bacterial strains from the human gut microbiota have potential as novel HDI therapeutics for disease areas involving host epigenetic aberrations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0201073

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Total HDAC inhibitory effects of supernatants from gut bacterial strains. (A) Screening of cell free supernatants (CFS) from 79 bacterial strains for total HDAC inhibition on whole HT-29 cells. Trichostatin A (TSA) is a negative control. (B) CFS of three selected bacterial strains tested for HDAC inhibition on HT-29 whole cell and HT-29 cell lysates. Trichostatin A (TSA) is used as a negative control. Significances tested against YCFA ** (p<0.005) *** (P<0.001).
Fig 1 Total HDAC inhibitory effects of supernatants from gut bacterial strains. (A) Screening of cell free supernatants (CFS) from 79 bacterial strains for total HDAC inhibition on whole HT-29 cells. Trichostatin A (TSA) is a negative control. (B) CFS of three selected bacterial strains tested for HDAC inhibition on HT-29 whole cell and HT-29 cell lysates. Trichostatin A (TSA) is used as a negative control. Significances tested against YCFA ** (p<0.005) *** (P<0.001).CC BY · PubMed Central
Fig 2 HDAC inhibition of supernatant from gut commensals is primarily driven by butyrate and valeric acid. (A) SCFA and MCFA production of three selected bacteria from screening panel. Strains were grown until stationary growth phase before SCFA and MCFA were measured in CFS. (B) Total HDI in HT-29 whole cells and cell lysate using 10 mM, 4 mM and 2 mM of butyrate, valeric and hexanoic acid. Trichostatin A (TSA) is used as a negative control. Significances tested against YCFA * (p<0.05) ** (p<0.005).
Fig 2 HDAC inhibition of supernatant from gut commensals is primarily driven by butyrate and valeric acid. (A) SCFA and MCFA production of three selected bacteria from screening panel. Strains were grown until stationary growth phase before SCFA and MCFA were measured in CFS. (B) Total HDI in HT-29 whole cells and cell lysate using 10 mM, 4 mM and 2 mM of butyrate, valeric and hexanoic acid. Trichostatin A (TSA) is used as a negative control. Significances tested against YCFA * (p<0.05) ** (p<0.005).CC BY · PubMed Central
Fig 3 HDAC inhibition of M. massiliensis MRx0029 is transferable to a microbiota model system (SimMi). (A) SCFA and MCFA concentrations of SimMi consortia (+/- MRx0029) on day 11 and 12 of continuous culture. (B) HDAC inhibition of CFS, obtained from SimMi consortia from day 12 with and without M. massiliensis MRx0029, on whole HT-29 cells and on HT-29 cell lysate. TSA is used as a negative control. Significances tested against YCFA * (p<0.05) ** (p<0.005) *** (P<0.001).
Fig 3 HDAC inhibition of M. massiliensis MRx0029 is transferable to a microbiota model system (SimMi). (A) SCFA and MCFA concentrations of SimMi consortia (+/- MRx0029) on day 11 and 12 of continuous culture. (B) HDAC inhibition of CFS, obtained from SimMi consortia from day 12 with and without M. massiliensis MRx0029, on whole HT-29 cells and on HT-29 cell lysate. TSA is used as a negative control. Significances tested against YCFA * (p<0.05) ** (p<0.005) *** (P<0.001).CC BY · PubMed Central
Fig 4 Supernatants of gut commensals selectively inhibit HDAC Class I enzymes—Specifically HDAC2 isoform. (A) Inhibition of different isoforms of class I (HDAC 1, HDAC2 and HDAC3) and class II (HDAC4, HDAC5, HDAC6 and HDAC9) HDACs by CFS of M. massiliensis MRx0029, R. intestinalis MRx0071, B. massiliensis MRx1342, SimMi (+/- M. massiliensis MRx0029) and dilutions of SCFA butyrate and valeric acid and MCFA hexanoic acid. (B-D) Specific inhibition of HDAC1 (B), HDAC2 (C) and HDAC3 (D) by CFS of bacterial strains M. massiliensis MRx0029, R. intestinalis MRx0071 and B. massiliensis MRx1342, SimMi (+/- M. massiliensis MRx0029) and different dilutions of SCFA butyrate and valeric acid and MCFA hexanoic acid. TSA is used as a negative control. Significances tested against YCFA * (p<0.05) ** (p<0.005) *** (P<0.001) **** (p<0.0001).
Fig 4 Supernatants of gut commensals selectively inhibit HDAC Class I enzymes—Specifically HDAC2 isoform. (A) Inhibition of different isoforms of class I (HDAC 1, HDAC2 and HDAC3) and class II (HDAC4, HDAC5, HDAC6 and HDAC9) HDACs by CFS of M. massiliensis MRx0029, R. intestinalis MRx0071, B. massiliensis MRx1342, SimMi (+/- M. massiliensis MRx0029) and dilutions of SCFA butyrate and valeric acid and MCFA hexanoic acid. (B-D) Specific inhibition of HDAC1 (B), HDAC2 (C) and HDAC3 (D) by CFS of bacterial strains M. massiliensis MRx0029, R. intestinalis MRx0071 and B. massiliensis MRx1342, SimMi (+/- M. massiliensis MRx0029) and different dilutions of SCFA butyrate and valeric acid and MCFA hexanoic acid. TSA is used as a negative control. Significances tested against YCFA * (p<0.05) ** (p<0.005) *** (P<0.001) **** (p<0.0001).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

Sorted by citations

See all 257

Metadata

Authors
Yuille, S., Reichardt, N., Panda, S., Dunbar, H., & Mulder, I. E.
Corresponding author
Mulder, Imke E.
Venue
PLOS ONE
Published
2018-07-27
Volume
13
Issue
7
Pages
e0201073
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2884838967
Cited by
257
References
48
Citations by year
2026: 23 · 2025: 23 · 2024: 46 · 2023: 48 · 2022: 34 · 2021: 27 · 2020: 37 · 2019: 18 · 2018: 1
FWCI
7.38
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
Keywords
histone deacetylase inhibitors, gut microbiota, class I HDACs, class II HDACs, short-chain fatty acids, butyrate, valeric acid, hexanoic acid, cell-free supernatant, microbial consortia, epigenetic regulation, host-microbe interactions
MeSH terms
Gastrointestinal Microbiome, Culture Media, Histone Deacetylases, Humans, Pentanoic Acids, Cell Culture Techniques, HT29 Cells, Butyric Acid, Megasphaera, Histone Deacetylase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review